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Patient outcomes influenced by reduced
lymphocyte counts after dimethyl
fumarate initiation
ABSTRACT
Objective: To examine the temporal profile of absolute and lymphocyte subset data from dimethyl
fumarate (DMF) start and relationships to disease behavior.
Methods: A retrospective study performed on patients with an existing diagnosis of MS and a his-
tory of DMF exposure from a single MS center. Demographic, laboratory, and corresponding clin-
ical relapse andMRI data were recorded from baseline and in 3–4-month intervals after treatment
initiation extending to 3 years. The Spearman rank coefficient and mixed-effects models were
used to assess longitudinal correlations between cell counts and measures of disease activity.
Results: A total of 292 patients with MS (228 women; median age at DMF initiation: 40.6 years,
range: 16.1–66.7 years) were identified. An increased risk of disease activity was associated
with higher absolute lymphocyte count (ALC) values at 3 months (p 5 0.001, OR: 1.82) and at
6 months (p 5 0.032, hazard ratio: 1.73). A reduced risk of disease evolution in patients with
lower ALC values , 1,200 cells/mL compared with midtier (1,210–1,800 cells/mL) and the
highest tertile (.1,810 cells/mL) was observed (p 5 0.01).
Conclusions: Reductions in ALC values at months 3 and 6 after treatment initiation appear to be
associated with improved clinical and radiologic outcomes. These data alone may help to provide
a better understanding of both the safety and efficacy of DMF. Neurol Neuroimmunol Neuroinflamm
2017;4:e397; doi: 10.1212/NXI.0000000000000397
GLOSSARY
ALC5 absolute lymphocyte count;DMF5 dimethyl fumarate;HR5 hazard ratio;NK5 natural killer;WBC5white blood cell.
Dimethyl fumarate (DMF), marketed commercially as Tecfidera, is a twice-daily, oral disease-
modifying therapy approved for the treatment of relapsing-remitting MS.While the exact mech-
anism of action is not entirely understood, DMF is known to cause reductions in white blood
cell (WBC) count and absolute lymphocyte count (ALC) values. Mean ALC reductions of
approximately 30% were previously observed within the first year of treatment.1 Significant
ALC reductions were also described, resulting in grade III lymphopenia (ALC ,500 cells/mL)
in approximately 5% of patients.1 Recent studies have also reported reductions in T cells and
B cells.2,3
Several cases of progressive multifocal leukoencephalopathy (PML) have occurred in DMF-
treated patients with sustained lymphopenia (.6 months). While most cases have occurred in
patients with ALC ,500 cells/mL, fumarate-related PML has developed with ALC values as
high as 792 cells/mL, highlighting the need for careful surveillance.4–6
Like many immunomodulatory treatments, DMF influences several targets, having anti-
inflammatory and immunomodulatory properties along with neuroprotective effects.7,8 How-
ever, this does not completely explain reductions in ALCs and lymphocyte subsets.2,3
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As T cells and B cells contribute to MS
pathogenesis, it is conceivable that some
degree of therapeutic effect could be related
to decreases in these cell counts. This investi-
gation aimed to evaluate the temporal profile
of absolute and lymphocyte subset changes
following exposure to DMF and the relation-
ship between these features and clinical and
radiologic measures of disease.
METHODS Clinical subjects. A retrospective chart review
was conducted on patients with relapsing-remitting MS and
a history of DMF exposure at the Clinical Center for Multiple
Sclerosis at UT Southwestern Medical Center in Dallas, Texas.
This study was approved by the UT Southwestern Medical
Center Institutional Review Board.
Demographic and laboratory data, including WBC, ALC,
CD3, CD4, CD8, natural killer (NK), and CD19 cell counts,
and corresponding clinical relapse and MRI data were recorded
as part of routine management. Data were obtained at baseline
and serially in 3–4-month intervals after treatment extending to
3 years (table 1). MRI data were acquired prior to DMF initia-
tion, 6 months after treatment, and annually thereafter. Disease
progression was defined by the presence of new or old neurologic
symptom attributable to CNS demyelination, persisting for .24
hours in the absence of fever or infection, or new (.3 mm2) or
enlarging lesions observed on repeat imaging of the brain or spinal
cord. Clinical relapses and new radiologic activity were verified by
the treating provider. Clinical relapse data were not included if
they occurred within the first 3 months of treatment. Radiologic
advancement was scored only if new imaging features supportive
of in situ demyelination were observed between the 6-month
post-DMF MRI and subsequent imaging studies.
Statistical analysis. Correlations between ALCs and clinical
outcomes were evaluated by the Spearman rank coefficient.
Mixed linear models were used to assess the time course of
ALC changes over multiple time points and the longitudinal cor-
relation of ALCs to patient outcome data. The association
between the ALC and time to a first clinical relapse or radiologic
advancement was assessed by a Cox model, and Kaplan-Meier
curves were generated to display the results. p Value of ,0.05
was considered statistically significant. Not all patients completed
scheduled serologic assessments or remained on therapy for $3
months. If ALC values were missing at month 6, ALC values
from month 3 were imputed for those who remained on therapy
to increase the available data in the survival analysis.
RESULTS Data were collected on 295 patients
with relapsing-remitting MS exposed to DMF.
Three patients were excluded because of insuffi-
cient laboratory and imaging assessments. A total of
292 patients served as the study cohort (228
women [78%], median age at DMF start date: 40.6
years, range: 16.1–66.7). The median disease
duration at DMF initiation was 4.5 years (0.0–
34.9) (table 2).
A correlation between WBC and ALC (r 5 0.46,
p , 0.001), CD3 (r 5 0.66, p , 0.001), CD4 (r 5
0.60, p , 0.001), CD8 (r 5 0.49, p , 0.001), and
CD19 (r5 0.55, p5 0.009) was found at baseline. At 6
months, a correlation between WBC and ALC (r 5
0.56, p , 0.001), CD3 (r 5 0.49, p 5 0.001), CD4
Table 1 Summary of data available at each time
point for leukocyte counts, absolute
lymphocyte counts (ALCs), and each
subpopulation
Time, min WBC ALC CD3 CD4 CD8 CD19 NK
0 266 263 50 50 50 22 22
3 152 148 45 46 46 22 21
6 122 119 40 40 41 19 19
9 81 80 35 34 34 11 9
12 143 144 61 61 61 28 26
18 130 129 65 65 65 34 31
24 108 107 77 77 77 37 35
30 75 75 67 67 67 47 44
36 34 34 29 29 29 26 25
Abbreviations: NK 5 natural killer; WBC 5 white blood cell.
Table 2 Demographic and clinical characteristic
data of the study cohort
Diagnosis: relapsing-remitting MS (n 5 292)
Age at first symptom, median years
(range)
32.1 (9.8–63.9)









African American 35 (12%)
Asian 3 (1%)
Native American 4 (1%)
Disease duration at Tecfidera
start
4.4 (0.003–34.94)
Time since last relapse at
Tecfidera start, y
1.25 (0.003–21.93)
History of exposure to prior DMT 238 (82%)
Teriflunomide (Aubagio) 10 (4%)
Interferon b-1 a (Avonex) 32 (11%)
Interferon b-1 b (Betaseron) 16 (5%)
Glatiramer acetate (Copaxone) 91 (31%)
Fingolimod (Gilenya) 10 (4%)
Interferon b-1 a (Rebif) 26 (9%)
Natalizumab (Tysabri) 48 (16%)
Other 5 (2%)
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(r 5 0.44, p 5 0.004), CD8 (r 5 0.50, p 5 0.001),
CD19 (r5 0.52, p5 0.023), and NK (r5 0.47, p5
0.048) cells was identified. In addition, a relationship
between NK cells and ALC (r 5 0.66, p 5 0.003),
CD3 (r 5 0.51, p 5 0.032), and CD4 (r 5 0.53,
p 5 0.026) was observed at 6 months.
Changes between baseline and 9 months were
observed in WBC (monthly loss [b]: 20.14, p ,
Figure Temporal profile of lymphocyte subsets and their relationship with clinical and radiologic measures of disease
Significant reductions in white blood cell count and lymphocyte subsets were observed from baseline to 9months (A; box plots display themean and SD at each time
point). Case processing summary demonstrating the time to first relapse according to absolute lymphocyte counts (ALCs) at months 3 and 6 after dimethyl fumarate
initiation alongwith the number of clinical and radiologic events identified by ALC thresholds (B). The time to a first new clinical or radiologic eventwas extendedwhen
ALCs were reduced at 3 and 6 months, independent of baseline lymphocyte values and key baseline demographic and clinical data. NK 5 natural killer.
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0.001), ALC (b: 20.09, p , 0.001), CD3 (b:
271.1, p , 0.001), CD4 (b: 243.2, p , 0.001),
and CD8 counts(b: 221.7, p , 0.001). A longitu-
dinal correlation between CD4 and CD19 subsets
during the first 9 months of treatment was found
(p , 0.001).
Time to first relapse was measured in accordance
with ALCs at baseline (n 5 247), 3 (n 5 148), and
6 months (n 5 118). A greater risk of relapse was
associated with higher ALCs at 3 months (p5 0.001,
hazard ratio [HR]: 1.82) and 6 months (p 5 0.032,
HR: 1.73). When considering patients with lympho-
cyte counts at 6 months (n 5 207), a decline in
relapse-free survival was seen in patients with higher
ALC values even after adjusting for age, sex, previous
disease-modifying therapy (DMT) exposure, prior
treatment type, and disease duration. Examination
by tertile indicated a reduced risk in patients with
lower ALC values , 1,200 cells/mL compared with
midtier (1,210–1,800 cells/mL) and the highest ter-
tile (.1,810 cells/mL) (p 5 0.01) (figure).
DISCUSSION Our findings revealed a meaningful
reduction in total WBC counts, ALCs, and all lym-
phocyte subsets as soon as 3 months following
DMF initiation; this pattern continued the first
9 months of treatment at which time counts began
to plateau. The temporal profile of ALC changes also
correlated with T- and B-cell subset data. Longitudi-
nal correlations between CD4 and CD19 counts at
baseline and month 9 of treatment were observed,
suggesting that the clinical surveillance of patients
may be effectively managed without lymphocyte
subsets.
Our data suggest that laboratory assessments every
6 months are likely sufficient for the routine manage-
ment of patients without lymphopenia, given the pro-
pensity for ALC values to stabilize after 9 months of
treatment, which is in alignment with current pack-
age insert recommendations.
Beyond our observations to improve on the effi-
ciency of the management of patients with MS trea-
ted with DMF, we identified an association
between ALC values and clinical and radiologic
markers of disease. Reductions in ALCs at months
3 and 6 after treatment were associated with
improved clinical and radiologic outcomes indepen-
dent of baseline lymphocyte counts, and ALCs
.1,800 cells/mL were more strongly associated with
new disease behavior. This observation differs from
previously published data that excluded new MRI
activity in the definition of disease evolution and
compared those with lymphopenia ($1 ALC ,
LLN) to those without (all ALCs $ LLN).9 The
other study correlated outcomes with lymphopenia
grades alone.10 Our findings may provide a more
refined estimate of the association between ALC val-
ues and clinical response, understanding the potential
compromise between safety and efficacy.
Our findings are limited by an assumption of full
patient compliance with DMF, as objective measures
of medication utilization beyond clinical inquiries
during office visits were not used. Consequently, dis-
ease behavior measured by clinical and radiologic
metrics could have been influenced by the degree of
medication compliance. A modest number of clinical
and radiologic events in total (n 5 45), the lack of
systematically acquired neuroimaging studies and
scheduled clinical assessments, and the use of multi-
ple commercial laboratories to acquire data serve as
potential limiting factors.
Finally, prospective studies are needed to confirm
these findings. These data aid in refining surveillance
recommendations and highlight the importance of
diligent monitoring of ALCs especially within the
first 9 months of treatment. ALCs alone may provide
a better understanding of both the safety and thera-
peutic effect of DMF.
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